PITTSBURGH — Mylan has launched the first generic version of a drug used to treat fungal infections, the company said Monday.
The drug maker announced the launch of voriconazole for oral suspension in the 40-mg-per-mL strength. The drug is the first generic version of Pfizer's Vfend, and as the first company to receive approval for a generic version, Mylan has 180 days in which to compete exclusively against Pfizer's product. The drug is used to treat invasive fungal infections.
The drug had sales of $17.1 million during the 12-month period that ended in June, according to IMS Health.